ABOUT HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY

The HeartMate 3™ LVAD with Full MagLev™ Flow Technology has significantly advanced the field of LVAD therapy, setting the standard with innovation and outstanding clinical outcomes that make a meaningful difference in your patients’ lives.1

This innovation includes Full MagLev Flow Technology, which maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.1

The HeartMate 3 LVAD is used for advanced heart failure patients needing short- or long-term mechanical circulatory support.

OUTCOMES MADE POSSIBLE BY FULL MAGLEV FLOW TECHNOLOGY

Full MagLev Flow Technology maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

  • Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways to reduce shear stress3
  • Intrinsic pulsatility to reduce stasis and minimize thrombus3,4
Cut across view of the HeartMate 3 Maglev Pump

SYSTEM OVERVIEW

Get to know the HeartMate 3™ LVAD:

Silhouette of figure with HeartMate 3 LVAD and components overlaid on his figure.

1. HeartMate 3 LVAD

Connected to the left side of the heart and moves oxygenated blood from the left ventricle to the rest of the body.

HeartMate 3 LVAD Pump

2. System Controller

Powers and controls the LVAD and is small enough to fit in a pocket. Includes emergency battery backup.

The controller of the HeartMate 3 LVAD.

3. Batteries

Provide up to 17 hours of uninterrupted power.

Two batteries for the HeartMate 3 LVAD.

4. Modular Driveline

Facilitates simple replacement of externalized portion.

Closeup of the modular driveline for the HeartMate 3 LVAD.

5. MPU

Plugs into an electrical socket to provide power while indoors, at rest or asleep. Small, lightweight and mobile, the unit is designed to be extremely durable.

Mobile power unit for the HeartMate 3 LVAD.

This device is commercially available for use in select international markets.

References

  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Abbott data on file.
  3. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375- 383.
  4. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist deviceinduced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.

Source : https://www.cardiovascular.abbott/